Boston, MA - More than 40 representatives of New Jersey’s leading life sciences companies, universities, service organizations, trade associations, state government and Choose New Jersey, Inc. are heading to Boston for BIO International 2018. The delegation will showcase the State’s wealth of assets and resources for the life sciences industry at the New Jersey Pavilion (Booth #1721) at the Boston Convention and Exhibition Center, June 5-7. Along with lead sponsors Choose New Jersey and BioNJ, state government sponsors include the New Jersey Business Action Center and the New Jersey Economic Development Authority (EDA).
On Tuesday June 5, New Jersey will kick off BIO 2018 with the launch of Research with NJ. Created by a team led by the EDA and the Office of the Secretary of Higher Education, the online portal facilitates access to research expertise and other assets at the State’s higher education institutions. It also serves to increase innovation exchange, establish greater collaboration between academia and industry, aid universities in managing the research enterprise and solidify New Jersey’s reputation as an innovation leader. Research with NJ is built on a software platform from global information analytics giant Elsevier.
During the world’s largest biotechnology conference, members of the New Jersey delegation will hold business meetings with company executives from around the world about the benefits of a New Jersey location. Partnering meetings and demonstrations of the Research with NJ portal will also be held at the 1,500-square-foot New Jersey Pavilion throughout BIO International 2018.
“BIO International provides the perfect venue to affirm our State’s leadership in the biopharmaceutical sector and demonstrate the strength of our innovation ecosystem,” said Jose Lozano, president and CEO of Choose New Jersey, Inc. “We are proud to travel with our delegation to showcase the wealth of assets, resources and support biotechnology companies can expect to tap into when they choose a New Jersey location.”
Home to the headquarters or major facilities of 13 of the top 20 biopharmaceutical companies and more than 3,200 life sciences establishments, companies that settle in New Jersey have access to high quality lab space, including incubator, intermediate and larger stand-alone space; attractive incentives, including those specially created to support start-up and early stage ventures; access to venture capital, as well as opportunities for collaboration with leading biopharmaceutical companies and research universities. Biotechnology companies in New Jersey also have access to an exceptional workforce that makes it easy to recruit top talent.
Organizations also represented in the delegation include Amicus Therapeutics, Celgene, Elsevier, Helsinn, Janssen Pharmaceutical Companies, Lab Owl Bioreactor Control System, Lowenstein Sandler, Morris County Economic Development Corporation and Precision Oncology.
Higher educational institutions represented in the delegation include Hackensack Meridian Health, New Jersey Innovation Institute, Princeton University, Rowan University, Rutgers, the State University of New Jersey and Stevens Institute of Technology.
“The annual BIO Convention has long been an important platform to showcase New Jersey’s dynamic life sciences ecosystem,” said BioNJ President and CEO, Debbie Hart. “We look forward to once again meeting with businesses and entrepreneurs from around the globe that may be interested in establishing a footprint in New Jersey. Home to more than 1,000 biopharmaceutical companies in over 3,200 facilities ― with over 1,000 drugs in development and nearly 50% of all new drug approvals in 2017― the Garden State continues to lead the way in medical innovation.”
To access more business news, visit njbmagazine.com
During the world’s largest biotechnology conference, members of the New Jersey delegation will hold business meetings with company executives from around the world about the benefits of a New Jersey location. Partnering meetings and demonstrations of the Research with NJ portal will also be held at the 1,500-square-foot New Jersey Pavilion throughout BIO International 2018.
“BIO International provides the perfect venue to affirm our State’s leadership in the biopharmaceutical sector and demonstrate the strength of our innovation ecosystem,” said Jose Lozano, president and CEO of Choose New Jersey, Inc. “We are proud to travel with our delegation to showcase the wealth of assets, resources and support biotechnology companies can expect to tap into when they choose a New Jersey location.”
Home to the headquarters or major facilities of 13 of the top 20 biopharmaceutical companies and more than 3,200 life sciences establishments, companies that settle in New Jersey have access to high quality lab space, including incubator, intermediate and larger stand-alone space; attractive incentives, including those specially created to support start-up and early stage ventures; access to venture capital, as well as opportunities for collaboration with leading biopharmaceutical companies and research universities. Biotechnology companies in New Jersey also have access to an exceptional workforce that makes it easy to recruit top talent.
Organizations also represented in the delegation include Amicus Therapeutics, Celgene, Elsevier, Helsinn, Janssen Pharmaceutical Companies, Lab Owl Bioreactor Control System, Lowenstein Sandler, Morris County Economic Development Corporation and Precision Oncology.
Higher educational institutions represented in the delegation include Hackensack Meridian Health, New Jersey Innovation Institute, Princeton University, Rowan University, Rutgers, the State University of New Jersey and Stevens Institute of Technology.
“The annual BIO Convention has long been an important platform to showcase New Jersey’s dynamic life sciences ecosystem,” said BioNJ President and CEO, Debbie Hart. “We look forward to once again meeting with businesses and entrepreneurs from around the globe that may be interested in establishing a footprint in New Jersey. Home to more than 1,000 biopharmaceutical companies in over 3,200 facilities ― with over 1,000 drugs in development and nearly 50% of all new drug approvals in 2017― the Garden State continues to lead the way in medical innovation.”
To access more business news, visit njbmagazine.com
